These results demonstrate that it is necessary to measure serum PLA2R antibody and renal PLA2R antigen in SS-MN patients, and more aggressive therapeutic strategies may be warranted for PLA2R-positive patients who fail to achieve renal remission. This evidence concerns the gene PLA2R1 and synovial sarcoma.